Summit Therapeutics revenue and financials
$17.31Change from previous close: +0.23%Absolute change: +$0.04
Fiscal year ending in December. Sources and method on the page Methodology and sources.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | FY to Jan 2019 | FY to Jan 2018 | FY to Jan 2017 | FY to Jan 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0.0 | 0.0 | 0.0 | 0.7 | 1.8 | 0.9 | 57.1 | 25.4 | 2.3 | 0.0 |
| Gross profit | — | — | — | 0.7 | 1.8 | — | 2.7 | -25.8 | -24.9 | -20.3 |
| Selling, general and administrative | 557 | 60.2 | 29.3 | 26.7 | 23.6 | — | — | — | — | — |
| Research and development | 538 | 151 | 59.5 | 52.0 | 85.4 | 53.3 | 52.0 | 29.0 | 19.0 | 16.9 |
| Operating income | -1,094 | -226 | -610 | -72.1 | -86.2 | -53.2 | 5.4 | — | — | — |
| EBIT | -1,094 | -211 | -88.7 | -63.6 | -86.2 | — | — | — | — | — |
| EBITDA | -1,094 | -211 | -88.5 | -62.4 | -84.8 | — | — | — | — | — |
| Interest expense | 0.0 | 8.7 | 16.5 | 4.4 | 0.2 | 0.3 | 0.6 | 1.2 | 0.9 | 2.9 |
| Pre-tax income | -1,080 | -221 | -615 | -78.8 | -88.6 | — | — | — | — | — |
| Income tax | 0.0 | 0.0 | 0.0 | — | 0.0 | -0.2 | -1.8 | -3.8 | -4.3 | 3.1 |
| Net income | -1,080 | -221 | -615 | -78.8 | -88.6 | -52.7 | 10.9 | -20.2 | -21.4 | -20.1 |
| Net income to common shareholders | -1,080 | -221 | -615 | -78.8 | -88.6 | — | — | — | — | — |
| Basic EPS | -1.44 | -0.31 | -0.99 | -0.41 | -0.67 | -0.76 | 0.63 | -0.31 | -0.35 | — |
| Diluted EPS | -1.44 | -0.31 | -0.99 | -0.41 | -0.67 | -0.76 | 0.63 | -0.31 | -0.35 | — |
| Average shares (basic) | 748 | 719 | 620 | 193 | 92.2 | — | — | — | — | — |
| Average shares (diluted) | 748 | 719 | 620 | 193 | 132 | 69.5 | 17.2 | — | — | — |